Nivolumab, Fluorouracil, and Interferon Alpha 2B for the Treatment of Unresectable Fibrolamellar Cancer
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Peking University
National Taiwan University Hospital
Merck Sharp & Dohme LLC
Zhejiang Cancer Hospital
Sun Yat-sen University
University of Birmingham
Sun Yat-sen University
Shandong Cancer Hospital and Institute
Sun Yat-sen University
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Sun Yat-sen University
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Sun Yat-sen University
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Shanghai Zhongshan Hospital
Sun Yat-sen University
Sun Yat-sen University
Guangxi Medical University
Guangxi Medical University
Sun Yat-sen University
Sun Yat-sen University
Eli Lilly and Company
Montefiore Medical Center
Kansai Hepatobiliary Oncology Group
Sun Yat-sen University
National Cancer Institute (NCI)
Peking University Cancer Hospital & Institute
Sun Yat-sen University
Sun Yat-sen University
Mayo Clinic
Seoul National University Hospital
National Cancer Institute (NCI)
Sun Yat-sen University
Alliance for Clinical Trials in Oncology
Eastern Hepatobiliary Surgery Hospital
Sun Yat-sen University
Seoul National University Hospital
Eastern Hepatobiliary Surgery Hospital
Roswell Park Cancer Institute
European Organisation for Research and Treatment of Cancer - EORTC
Stanford University
National Institutes of Health Clinical Center (CC)
Shenzhen Kangzhe Pharmaceutical Co., Ltd.
Sanofi
National Cancer Institute (NCI)
Kindai University
Sanofi
Shanghai Jiao Tong University School of Medicine